# US Onychomycosis Market

> US Onychomycosis Market Research Report Information By Type (Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Endonyx Onychomycosis (EO), And Others), By Treatment (Oral And Topical) And By Region (US) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.2%
- **2024:** $ 437.85 Million
- **2025:** $ 460.62 Million
- **2035:** $ 764.87 Million
- **Key Players:** Bayer AG (DE), Novartis AG (CH), Johnson & Johnson (US), GlaxoSmithKline plc (GB), Pfizer Inc. (US), Sanofi S.A. (FR), Merck & Co., Inc. (US), AbbVie Inc. (US)

**Report ID:** MRFR/Pharma/1895-CR · **Pages:** 30 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** January 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-onychomycosis-market-2535

---

## Market Summary

## **US Onychomycosis Market Overview**

US Onychomycosis Market Size was valued at USD 1.62 Billion in 2023. The Onychomycosis market industry is projected to grow from USD 1.75 Billion in 2024 to USD 3.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.44% during the forecast period (2024 - 2032). Increasing prevalence of onychomycosis and chronic illness, increased R&D for the discovery of innovative medications are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review Lupin announced the US launch of Tavaborole Topical Solution, 5% in July 2021, following its approval by the United States Food and Drug Administration (FDA). The substance will be produced at Lupin's facility in Pithampur, India. Tavaborole Topical Solution, 5%, is the generic equivalent of Kerydin® Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. It is an oxaborole antifungal that is authorized for the topical treatment of onychomycosis of the toenails caused by Trichophyton rubrum or Trichophyton mentagrophytes.

The estimated annual sales of Tavaborole Topical Solution (RLD: Kerydin®), 5% in the United States are $53 million (IQVIA MAT May 2021).

## **US Onychomycosis Market Trends**

### **Growing prevalence for onychomycosis is driving the market growth**

Market CAGR for onychomycosis is being driven by the rising cases for onychomycosis. Onychomycosis is becoming more common. Toenail onychomycosis infection is far more common than infection in fingernails. The rising prevalence of dermatophyte-caused nail fungal infection and a large increase in the number of prescriptions are likely to drive the market. Onychomycosis is growing increasingly common, particularly among vulnerable groups. It is difficult to treat since most antifungal [drugs](../../../reports/drug-device-combination-market-6946) are ineffective. Nondermatophyte molds and mixed infection onychomycosis increase antifungal resistance because they are usually underestimated and ignored due to misdiagnosis.

Furthermore, the entry of generic rivals into the market stifles market growth.  This is likely to boost demand for dermatophytic onychomycosis therapy during the projected period. Furthermore, the increased incidence of diabetes contributes to an increase in the prevalence of dermatophytic infection. The rising inclination for topical treatment solutions is a primary dermatophytic onychomycosis treatment market trend.

Because oral antifungal medications have been linked to liver damage, they are not recommended for individuals suffering from liver or heart problems.  According to a 2017 poll of dermatologists and podiatrists in the United States performed by Moberg Pharma AB, 7 out of 10 clinicians avoid prescription oral terbinafine due to the risk of liver damage. Furthermore, dermatologists and podiatrists throughout the world believe that better topical therapies than those now available are desperately needed. A progressive move towards topical solutions has resulted in huge market prospects for topical medications and active R&D for the creation of effective nail lacquers.

The Onychomycosis Market in the United States is expanding as individuals become more health-conscious and have more disposable income. However, a lack of knowledge and pharmaceutical side effects are possible hurdles to expanding the US Onychomycosis Market. The need for medicines is well recognized because of the high incidence of onychomycosis infections worldwide. Small research-based pharmaceutical and biotechnology businesses are broadly leading R&D, while larger players are increasingly focused on more lucrative goods.

Furthermore, larger businesses are utilizing acquisition techniques to expand their antifungal pipeline.  During the projected period, the treatments market is expected to develop due to high demand for these goods and rising usage. The growing use of immunosuppressive and antineoplastic drugs, broad-spectrum antibiotics, and prosthetic devices has resulted in a rise in fungal infections. Other variables influencing sales include fewer visits to healthcare facilities to reduce cross-contamination and fewer visits to pharmacies. Furthermore, compared to other chronic disorders, onychomycosis receives far less attention than it deserves.

Market sales have fallen even further as the disease's severity has decreased over the year covid-19. The oral treatment of onychomycosis is a market growth accelerator in the United States. Thus, driving the Onychomycosis market revenue.

## **US Onychomycosis Market Segment Insights**

### **US Onychomycosis Type Insights**

The US Onychomycosis market segmentation, based on type includes distal subungual onychomycosis (DSO), white superficial onychomycosis (WSO), proximal subungual onychomycosis (PSO), endonyx onychomycosis (EO), and others. The distal subungual onychomycosis (DSO) segment dominated the market, accounting for 35% of market revenue. The segment's dominance is linked to the FDA's increasing prevalence and quantity of generic approvals to fulfil rising demand. Furthermore, the number of pipeline items is increasing to match the increased need for effective treatments. The most prevalent kind of fungal nail infection is distal lateral subungual onychomycosis (DLSO).

The fungus in DLSO usually spreads from the epidermis to the underside of the nail, where the nail meets the nail bed. The symptoms of DLSO are caused by inflammation in certain sections of the nail.

### **US Onychomycosis Treatment Insights**

The US Onychomycosis market segmentation, based on treatment, includes oral and topical. The oral category generated the most income (70.4%). The segment's rise is linked to higher cure rates and shorter treatment periods than topical antifungals, although they have major side effects such as hepatotoxicity and drug interactions. Terbinafine hydrochloride (Lamisil) is the most often used treatment for onychomycosis. To address the increased occurrence of onychomycosis, several generic manufacturers are releasing oral treatments.Because oral medications have negative side effects such as liver damage, many dermatologists and podiatrists prefer to prescribe topical treatments.

This, together with increased research for topical medicine development, is likely to promote the growth of the tablets market.

**Figure 1: US Onychomycosis Market, by Treatment, 2022 & 2032 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

## **US Onychomycosis Key Market Players & Competitive Insights**

Leading market companies are extensively spending R&D on increasing their product lines, which will help the Onychomycosis market grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The Onychomycosis industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate. Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Onychomycosis industry to serve clients and expand the market sector. The Onychomycosis industry has provided some of the most important benefits recently.

Major players in the Onychomycosis market, including Pfizer, and others, are attempting to increase market demand by investing in research and development operations. Their global portfolio comprises pharmaceuticals, vaccines, and several of the most well-known consumer healthcare goods on the market. Every day, Pfizer associates work in established and emerging markets to promote wellness, prevention, treatments, and cures for today's most dreaded illnesses. Pfizer before making an employment offer. In October 2020, Pfizer Inc. announced the start of clinical trials for onychomycosis. The first entailed investigating if the AN2690 topical solution is an effective therapy for toenail onychomycosis.

The second was an open-label trial to assess the safety and pharmacokinetics of tavaborole 5% topical solution in children and adolescents with distal subungual onychomycosis of the toe. Almirall is a multinational biopharmaceutical firm specializing in skin care. They work with scientists and healthcare experts to answer patients' needs with science to enhance their lives. Their Noble Purpose is at the heart of their work: "Transform the patients' world by assisting them in realizing their hopes and dreams for a healthy life." They invest in distinctive and ground-breaking medical dermatological products to deliver creative solutions to needy people.

Throughout its 77-year existence, Almirall has maintained a strong focus on patient requirements. Almirall has a direct presence in 21 countries and strategic relationships in over 70 more, with about 1,800 workers across 13 companies.  In 2020, total revenues were 814.5 million euros. In July 2020, Almirall S.A. and Kaken Pharmaceutical (KKPCF) announced signing a license and distribution agreement. Kaken Pharmaceutical granted Almirall the exclusive right to develop and commercialize an efinaconazole topical formulation. This active principle, a triazole antifungal chemical developed by Kaken Pharmaceutical, treats onychomycosis, a fungal nail infection.

It possesses exceptional nail-penetrating characteristics due to its low binding affinity for keratin, the primary component of nails.

### **Key Companies in the Onychomycosis market include**

- Johnson & Johnson
- Novartis AG
- Valeant Pharmaceuticals
- [Pfizer Inc.](https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_anacor)
- Anacor Pharmaceuticals
- Galderma S.A.
- Moberg Pharma AB
- Bayer AG
- Dr. Reddy’s Laboratories Ltd.
- Cipla Ltd.
- Medimetriks Pharmaceuticals, Inc.

## **US Onychomycosis Industry Developments**

**July 2021:**Alembic announced that its joint venture Aleor Dermaceuticals Limited (Aleor) took tentative approval from the US Food & Drug Administration (US FDA) for an abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the medical management of this condition in toenail.

**April 2021:**Lupin Limited (Lupin) announced today that the US Food and Drug Administration had approved its Tavaborole Topical Solution, 5%, to market as a generic counterpart of Anacor Pharmaceuticals, Inc.'s Kerydin Topical Solution, 5%.

## **US Onychomycosis Market Segmentation**

### **US Onychomycosis Type Outlook**

- Distal Subungual Onychomycosis (DSO)
- White Superficial Onychomycosis (WSO)
- Proximal Subungual Onychomycosis (PSO)
- Endonyx Onychomycosis (EO)
- Others

### **US Onychomycosis Treatment Outlook**

- Oral
- Topical

## Market Drivers

### Impact of Aging Population

The aging population in the US is a crucial factor influencing the onychomycosis market. As individuals age, they become more susceptible to various health conditions, including fungal infections of the nails. The demographic shift towards an older population is expected to increase the prevalence of onychomycosis, thereby driving demand for effective treatment options. It is estimated that nearly 50% of individuals over the age of 70 may experience this condition. This demographic trend presents both challenges and opportunities for healthcare providers and pharmaceutical companies. The onychomycosis market must adapt to meet the needs of this growing population segment, which may include developing targeted therapies and enhancing patient education regarding prevention and treatment.

### Rising Healthcare Expenditure

The upward trend in healthcare expenditure in the US is a significant driver for the onychomycosis market. Increased spending on healthcare services and pharmaceuticals allows for greater access to advanced treatment options for patients suffering from onychomycosis. As healthcare budgets expand, there is a corresponding rise in the availability of innovative therapies and diagnostic tools. This financial commitment from both public and private sectors is likely to enhance the overall quality of care for patients. Furthermore, the emphasis on preventive healthcare may lead to earlier diagnosis and treatment of onychomycosis, ultimately benefiting the market. The onychomycosis market stands to gain from this trend, as it aligns with broader healthcare initiatives aimed at improving patient outcomes.

### Increasing Prevalence of Onychomycosis

The rising incidence of onychomycosis in the US is a primary driver for the onychomycosis market. Studies indicate that approximately 10% of the adult population is affected by this fungal infection, with the prevalence increasing with age. This growing demographic of affected individuals necessitates effective treatment options, thereby propelling market growth. The onychomycosis market is projected to expand as healthcare providers recognize the need for improved diagnostic and therapeutic solutions. Furthermore, the increasing awareness of foot health and hygiene among the population contributes to the demand for antifungal treatments, which are essential in managing this condition. As the population ages, the burden of onychomycosis is likely to escalate, further driving the market's expansion.

### Technological Innovations in Treatment

Technological advancements in the development of antifungal agents and treatment modalities are significantly influencing the onychomycosis market. Recent innovations include the introduction of laser therapy and novel topical formulations that enhance drug delivery and efficacy. These advancements not only improve patient outcomes but also attract investment in research and development, fostering a competitive landscape. The market is witnessing a shift towards more effective and less invasive treatment options, which could potentially increase patient compliance. As a result, the onychomycosis market is expected to benefit from these innovations, with a projected growth rate of around 7% annually over the next few years. This trend indicates a promising future for both patients and manufacturers in the sector.

### Growing Demand for Over-the-Counter Treatments

The increasing preference for over-the-counter (OTC) treatments among consumers is shaping the onychomycosis market. Patients are increasingly seeking accessible and convenient solutions for managing their condition without the need for prescription medications. This trend is driven by a combination of factors, including rising healthcare costs and a desire for self-management. The OTC segment is expected to witness substantial growth, with estimates suggesting it could account for over 30% of the total market share by 2026. This shift not only reflects changing consumer behavior but also indicates a potential for increased competition among manufacturers to develop effective OTC antifungal products. Consequently, the onychomycosis market is likely to evolve in response to these consumer preferences.

## Future Outlook

The onychomycosis market is projected to grow at a 5.2% CAGR from 2025 to 2035, driven by increasing prevalence, innovative treatments, and rising awareness.

**New opportunities:**

- Development of telehealth platforms for remote consultations and prescriptions. Investment in advanced antifungal drug formulations targeting resistant strains. Expansion of over-the-counter treatment options in retail pharmacies.

By 2035, the market is expected to achieve substantial growth, reflecting evolving consumer needs and treatment advancements.

## Segment Insights

### By Type: Distal Subungual Onychomycosis (Largest) vs. Candida Onychomycosis (Fastest-Growing)

In the US onychomycosis market, the segment distribution reveals that Distal Subungual Onychomycosis (DSO) holds the largest market share, significantly outpacing other types. Following DSO, White Superficial Onychomycosis (WSO) and Proximal Subungual Onychomycosis (PSO) exhibit moderate shares, while Candida Onychomycosis, though smaller in scale, is poised for rapid growth. The remaining category, 'Others', covers various sporadic forms but contributes minimally to the overall distribution.

Growth trends indicate a shift towards Candida Onychomycosis, driven by rising awareness and increasing diagnosis rates. Factors such as growing incidences related to other health conditions and the availability of innovative treatment options are supporting this segment's expansion. Additionally, the demand for effective therapies in difficult-to-treat cases is facilitating a competitive landscape among different treatment modalities.

Distal Subungual Onychomycosis (Dominant) vs. Candida Onychomycosis (Emerging)

Distal Subungual Onychomycosis (DSO) is characterized by its prominence as the most common type of nail fungal infection, making it a dominant segment in the market. It often leads to significant nail deformities if left untreated, necessitating effective therapeutic interventions. On the other hand, Candida Onychomycosis is emerging rapidly, attributed to an increase in diabetes and immunocompromised patients who are more susceptible to yeast infections. This growth is supported by improvements in antifungal treatments that specifically target Candida species, offering effective solutions that appeal to healthcare providers and patients alike. As awareness of fungal nail infections rises, both segments demonstrate unique and critical roles in the US onychomycosis market.

### By Treatment Type: Drug Treatment (Largest) vs. Topical Therapy (Fastest-Growing)

In the US onychomycosis market, Drug Treatment is the largest segment, dominating market share due to established efficacy and widespread availability. It constitutes a significant portion of the treatment landscape, primarily driven by prescription medications. In contrast, Topical Therapy has emerged as the fastest-growing segment, appealing to patients seeking less invasive and easy-to-use options. This trend reflects shifts in patient preferences towards more convenient treatment solutions.

The growth trends within these segments are influenced by several factors, including the increasing incidence of onychomycosis, heightened awareness of treatment options, and advancements in drug formulations. Moreover, marketing strategies targeting both healthcare professionals and patients further bolster the adoption of topical treatments, enhancing their market trajectory. As dermatological innovations continue, both segments are poised for ongoing development and expansion in the competitive landscape.

Drug Treatment: Dominant vs. Topical Therapy: Emerging

Drug Treatment represents the dominant market force within the US onychomycosis market, characterized by a range of prescription antifungal medications that offer robust efficacy against fungal infections. This segment benefits from established clinical guidelines and a strong base of healthcare provider recommendations. On the other hand, Topical Therapy, labeled as an emerging option, has gained traction due to its user-friendly application and minimal side effects. Patients increasingly opt for topical solutions as first-line treatments, leading to accelerated growth in this segment. Both Drug Treatment and Topical Therapy contribute uniquely to the market, addressing diverse patient needs while adapting to the changing landscape of onychomycosis treatments.

### By End User: Retail Pharmacies (Largest) vs. Hospital Pharmacies (Fastest-Growing)

In the US onychomycosis market, the distribution of market share among end users is notably led by retail pharmacies, which command a significant portion due to their widespread accessibility and consumer preference. [Retail pharmacies](https://www.marketresearchfuture.com/reports/retail-pharmacy-market-22432) are preferred by consumers for their convenience and broad range of available treatments. In contrast, hospital pharmacies hold a smaller share but are experiencing rapid growth, driven by the increasing prevalence of onychomycosis requiring more specialized treatment options that hospitals can provide. The growth trends within this segment demonstrate that hospital pharmacies are becoming increasingly essential in the treatment landscape for onychomycosis. Factors contributing to this growth include improved healthcare access, a rise in chronic illnesses that exacerbate fungal infections, and a growing awareness among healthcare professionals regarding effective treatment protocols. As hospitals enhance their pharmacy services, they are likely to attract more patients, thus accelerating their growth trajectory in the coming years.

Retail Pharmacies: Dominant vs. Hospital Pharmacies: Emerging

Retail pharmacies are characterized by their extensive availability, making them the dominant force in the US onychomycosis market. They cater to a wide demographic, providing over-the-counter treatments that are convenient and easily accessible to consumers. The rise in self-medication trends has further solidified their position. Conversely, hospital pharmacies are emerging as a vital segment, focusing on more complex prescriptions and acute health concerns. They offer specialized treatments and have the potential to build strong patient relationships through targeted therapeutic approaches. This segment is poised for growth as more healthcare providers recognize the need for tailored treatment solutions for patients suffering from onychomycosis.

## Regional Market Share Analysis

### North America : Market Leader in Onychomycosis

The North American onychomycosis market is primarily driven by increasing awareness of fungal infections and advancements in treatment options. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 15%. Regulatory support from agencies like the FDA has accelerated the approval of new therapies, enhancing market growth. The rising prevalence of diabetes and other conditions that predispose individuals to fungal infections further fuels demand. In this region, the competitive landscape is characterized by the presence of major pharmaceutical companies such as Janssen Pharmaceuticals, Valeant Pharmaceuticals, and Novartis. These key players are actively involved in research and development to introduce innovative treatments. The market is also witnessing collaborations and partnerships aimed at expanding product portfolios and improving patient outcomes. The focus on effective and safe treatment options continues to shape the competitive dynamics.

### Europe : Emerging Market with Growth Potential

The European onychomycosis market is experiencing significant growth, driven by an aging population and increasing healthcare expenditure. Germany and France are the largest markets, holding approximately 30% and 25% of the market share, respectively. Regulatory bodies in Europe, such as the European Medicines Agency (EMA), are facilitating the approval of new antifungal treatments, which is expected to boost market growth. The rising incidence of onychomycosis, particularly among the elderly, is a key demand driver. Leading countries in this region include Germany, France, and the UK, with a competitive landscape featuring major players like Bayer and Galderma. The market is characterized by a mix of established pharmaceutical companies and emerging biotech firms focusing on innovative therapies. The presence of robust healthcare systems and increasing awareness about fungal infections are further enhancing the market's potential. Collaboration among stakeholders is also fostering advancements in treatment options.

### Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific onychomycosis market is witnessing rapid growth, driven by rising disposable incomes and increasing awareness of fungal infections. Countries like Japan and Australia are leading the market, accounting for approximately 25% and 20% of the market share, respectively. The region's growth is further supported by favorable regulatory frameworks that encourage the introduction of new therapies. The increasing prevalence of onychomycosis, particularly in humid climates, is a significant demand driver. In this region, the competitive landscape is evolving, with both multinational corporations and local players vying for market share. Key players such as Pfizer and Merck are actively involved in developing innovative treatment options. The market is characterized by a growing focus on patient-centric solutions and the integration of digital health technologies to improve treatment adherence and outcomes. The collaboration between healthcare providers and pharmaceutical companies is also enhancing the overall market dynamics.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa onychomycosis market is in its nascent stages, facing challenges such as limited access to healthcare and varying levels of awareness about fungal infections. South Africa and the UAE are the leading markets, holding approximately 20% and 15% of the market share, respectively. The growth potential is significant, driven by increasing healthcare investments and initiatives aimed at improving public health. Regulatory bodies are beginning to recognize the importance of antifungal treatments, which may catalyze market development. The competitive landscape is characterized by a mix of local and international players, with companies like Amgen and Sanofi making strides in the region. The market is gradually evolving, with a focus on educating healthcare professionals and patients about onychomycosis. The presence of a growing middle class and increasing healthcare access are expected to drive future growth, although challenges remain in terms of infrastructure and awareness.

## Competitive Benchmarking

The onychomycosis market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on expanding therapeutic options. Key players such as Bayer AG (DE), Novartis AG (CH), and Johnson & Johnson (US) are actively shaping the market dynamics through their distinct operational strategies. Bayer AG (DE) emphasizes research and development, particularly in antifungal therapies, while Novartis AG (CH) focuses on leveraging its extensive pipeline to introduce novel treatments. Johnson & Johnson (US) appears to be enhancing its market presence through strategic acquisitions and collaborations, thereby fostering a robust competitive environment that encourages innovation and diverse treatment options.The business tactics employed by these companies include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in a moderately fragmented market. The competitive structure is influenced by the collective actions of these key players, who are not only vying for market share but also striving to establish themselves as leaders in therapeutic advancements. This dynamic fosters a landscape where innovation and operational efficiency are paramount.

In October  Bayer AG (DE) announced a partnership with a biotech firm to co-develop a new topical antifungal treatment aimed at improving patient compliance and efficacy. This strategic move underscores Bayer's commitment to enhancing its product portfolio and addressing unmet medical needs in the onychomycosis segment. The collaboration is expected to leverage both companies' strengths, potentially accelerating the development timeline and market entry of the new therapy.

In September  Novartis AG (CH) launched a digital health initiative aimed at improving patient engagement and adherence to onychomycosis treatments. This initiative integrates mobile health technologies to provide patients with personalized treatment plans and reminders. The strategic importance of this move lies in its potential to enhance treatment outcomes and patient satisfaction, thereby positioning Novartis as a forward-thinking leader in the market.

In August  Johnson & Johnson (US) expanded its product line by acquiring a small pharmaceutical company specializing in innovative antifungal formulations. This acquisition not only broadens Johnson & Johnson's therapeutic offerings but also strengthens its competitive edge by incorporating cutting-edge technology into its existing portfolio. The strategic importance of this acquisition is evident in its potential to enhance market share and drive revenue growth in the onychomycosis segment.

As of November  the competitive trends in the onychomycosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming more prevalent, facilitating knowledge sharing and resource optimization among key players. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability, reflecting a broader shift in the pharmaceutical landscape.

## Recent News & Developments

**July 2021:**Alembic announced that its joint venture Aleor Dermaceuticals Limited (Aleor) took tentative approval from the US Food & Drug Administration (US FDA) for an abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the medical management of this condition in toenail.

**April 2021:**Lupin Limited (Lupin) announced today that the US Food and Drug Administration had approved its Tavaborole Topical Solution, 5%, to market as a generic counterpart of Anacor Pharmaceuticals, Inc.'s Kerydin Topical Solution, 5%.

## Report Scope

| MARKET SIZE 2024 | 437.85(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 460.62(USD Million) |
| MARKET SIZE 2035 | 764.87(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bayer AG (DE), Novartis AG (CH), Johnson & Johnson (US), GlaxoSmithKline plc (GB), Pfizer Inc. (US), Sanofi S.A. (FR), Merck & Co., Inc. (US), AbbVie Inc. (US) |
| Segments Covered | Type, Treatment Type, End User |
| Key Market Opportunities | Emerging antifungal therapies and telehealth solutions enhance treatment accessibility in the onychomycosis market. |
| Key Market Dynamics | Rising consumer awareness drives demand for innovative treatments in the onychomycosis market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US onychomycosis market in 2024?**
A: The overall market valuation was $437.85 Million in 2024.

**Q: What is the projected market size for the US onychomycosis market by 2035?**
A: The projected valuation for 2035 is $764.87 Million.

**Q: What is the expected CAGR for the US onychomycosis market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 5.2%.

**Q: Which segment had the highest valuation in the US onychomycosis market in 2024?**
A: In 2024, the Drug Treatment segment had a valuation of $200.0 - $350.0 Million.

**Q: What are the key players in the US onychomycosis market?**
A: Key players include Bayer AG, Novartis AG, Johnson & Johnson, GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Merck & Co., Inc., and AbbVie Inc.

**Q: How does the valuation of Distal Subungual Onychomycosis compare to other types in 2024?**
A: Distal Subungual Onychomycosis was valued at $150.0 - $270.0 Million, making it one of the higher segments.

**Q: What is the valuation range for Topical Therapy in the US onychomycosis market?**
A: Topical Therapy had a valuation range of $150.0 - $300.0 Million in 2024.

**Q: What is the expected growth trend for the US onychomycosis market from 2025 to 2035?**
A: The market is expected to grow steadily, reflecting a CAGR of 5.2% from 2025 to 2035.

**Q: Which end user segment is projected to have the highest valuation in 2024?**
A: Retail Pharmacies are projected to have the highest valuation, ranging from $200.0 - $350.0 Million.

**Q: What is the valuation range for Candida Onychomycosis in 2024?**
A: Candida Onychomycosis was valued between $70.0 - $130.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-onychomycosis-market-2535*